[go: up one dir, main page]

PE20010494A1 - Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis - Google Patents

Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis

Info

Publication number
PE20010494A1
PE20010494A1 PE2000000799A PE0007992000A PE20010494A1 PE 20010494 A1 PE20010494 A1 PE 20010494A1 PE 2000000799 A PE2000000799 A PE 2000000799A PE 0007992000 A PE0007992000 A PE 0007992000A PE 20010494 A1 PE20010494 A1 PE 20010494A1
Authority
PE
Peru
Prior art keywords
alkyl
pyridazines
ring
substitute
nr3cor6
Prior art date
Application number
PE2000000799A
Other languages
English (en)
Inventor
Stephen James Boyer
Jacques P Dumas
Holia N Hatoum-Mokdad
Teddy Kite Joe
Ning Su
Wendy Lee
Dhanapalan Nagarathnam
Robert N Sibley
Harold C E Kluender
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE20010494A1 publication Critical patent/PE20010494A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A PIRIDAZINAS SUSTITUIDAS Y FUSIONADAS DE FORMULA I, DONDE R1 Y R2 SON H, ALQUILO, GRUPO a, b, T1=T1-T1=T1; 1-2 DEL ANILLO T1 SON N Y LOS OTROS SON CH; m ES 0-4; G1 ES N(R6)2, NR3COR6, HALOGENO, ALQUILO, ENTRE OTROS; R3 ES H, ALQUILO; R6 ES H, ALQUILO, ARILO, ARILALQUILO; R4 ES H, HALOGENO, ALQUILO; p ES 0-2; X ES O, S, NH; Y ES (C(R4)2)n-S(O)p-(HETEROARILO DE 5 MIEMBROS)-(C(R4)2)s-, ENTRE OTROS; n Y s SON 0-2; G2 ES CN, CO2R3, CON(R6)2, ENTRE OTROS; A, B, D, E, L SON N, CH; NITROGENO EN EL ANILLO A, B, D, E Y L ES 1-3; L ES CH, UNO DE A Y D ES N; q ES 0-2; G3 ES ALQUILO, NR3COR6, ALQUILO, ENTRE OTROS; J ES ARILO, PIRIDILO, CICLOALQUILO; q` ES LA CANTIDAD DE SUSTITUYENTES G4 EN EL ANILLO J, ES 0-5; G4 ES N(R6)2, NR3COR6, HALOGENO, ALQUILO, ENTRE OTROS; CUANDO 2 GRUPOS R6 SON ALQUILO, SITUADOS EN N, PUEDEN ESTAR LIGADOS MEDIANTE UN ENLACE, O, S, NR3 PARA FORMAR UN HETEROCICLO QUE CONTIENE N DE 5-7 ATOMOS EN EL ANILLO. SON COMPUESTOS PREFERIDOS METILAMIDA DE ACIDO 4-[4-(4-CLOROFENILAMINO)FTALAZIN-1-METIL]PIRIDIN-2-IL CARBOXILICO, 1-(4-CLOROFENILAMINO)-4-(3-PIRIDILMETOXI)FTALAZINA, ENTRE OTROS. EL COMPUESTO I TIENE ACTIVIDAD INHIBITORIA DE ANGIOGENES Y PUEDE SER UTIL PARA EL TRATAMIENTO DE CRECIMIENTO DE TUMOR, RETINOPATIA, OCLUSION ISQUEMICA RETINAL VENOSA
PE2000000799A 1999-08-10 2000-08-08 Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis PE20010494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37132299A 1999-08-10 1999-08-10

Publications (1)

Publication Number Publication Date
PE20010494A1 true PE20010494A1 (es) 2001-06-27

Family

ID=23463486

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000000799A PE20010494A1 (es) 1999-08-10 2000-08-08 Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis

Country Status (19)

Country Link
EP (1) EP1208096B1 (es)
JP (1) JP2003506447A (es)
KR (1) KR20020019969A (es)
CN (1) CN1378543A (es)
AR (1) AR025068A1 (es)
AT (1) ATE265448T1 (es)
AU (1) AU775237B2 (es)
BR (1) BR0013113A (es)
CA (1) CA2381621A1 (es)
CO (1) CO5180637A1 (es)
DE (1) DE60010280T2 (es)
ES (1) ES2219382T3 (es)
IL (1) IL147885A0 (es)
MX (1) MXPA02001324A (es)
NO (1) NO20020569L (es)
NZ (1) NZ517087A (es)
PE (1) PE20010494A1 (es)
WO (1) WO2001010859A1 (es)
ZA (1) ZA200200691B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6689883B1 (en) 1999-09-28 2004-02-10 Bayer Pharmaceuticals Corporation Substituted pyridines and pyridazines with angiogenesis inhibiting activity
AR025752A1 (es) * 1999-09-28 2002-12-11 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
US7977333B2 (en) 2000-04-20 2011-07-12 Bayer Healthcare Llc Substituted pyridines and pyridazines with angiogenesis inhibiting activity
GB0111078D0 (en) * 2001-05-04 2001-06-27 Novartis Ag Organic compounds
EP1712234B1 (en) * 2001-09-12 2009-01-28 Novartis AG Use of 4-Pyridylmethylphthalazines for Renal Cancer Treatment
WO2003059354A2 (en) * 2001-12-21 2003-07-24 Bayer Pharmaceuticals Corporation Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
US7015227B2 (en) 2002-06-21 2006-03-21 Cgi Pharmaceuticals, Inc. Certain amino-substituted monocycles as kinase modulators
ATE359789T1 (de) * 2002-09-24 2007-05-15 Novartis Pharma Gmbh Verwendung von 4-pyridylmethyl-phthalazin- derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
EP1562591A1 (en) * 2002-11-12 2005-08-17 Novartis AG Treatment of mesothelioma
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP5516397B2 (ja) 2007-04-05 2014-06-11 アムジエン・インコーポレーテツド オーロラキナーゼ調節物質及び使用方法
PL2167549T3 (pl) 2007-06-19 2013-03-29 Rynel Inc Materiały zawierające cząstki polimeru rozpuszczalnego w wodzie oraz sposoby ich wytwarzania i stosowania
MX2010010151A (es) 2008-03-20 2010-10-25 Amgen Inc Moduladores de cinasa aurora y metodo de uso.
ES2433469T3 (es) * 2008-08-04 2013-12-11 Amgen Inc. Moduladores de la aurora cinasa y métodos de uso
US9126935B2 (en) 2008-08-14 2015-09-08 Amgen Inc. Aurora kinase modulators and methods of use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1293565A (en) * 1969-05-03 1972-10-18 Aspro Nicholas Ltd Aminophthalazines and pharmaceutical compositions thereof
JPH03106875A (ja) * 1989-09-20 1991-05-07 Morishita Pharmaceut Co Ltd 1―(3―ピリジルメチル)フタラジン誘導体
JPH0673022A (ja) * 1992-08-27 1994-03-15 Kumiai Chem Ind Co Ltd ピリミジンまたはトリアジン誘導体及び除草剤
JP3919835B2 (ja) * 1994-08-09 2007-05-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 縮合ピリダジン系化合物
CN1151136C (zh) * 1994-08-09 2004-05-26 卫材株式会社 缩合哒嗪系化合物
CO4950519A1 (es) * 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
JP4673977B2 (ja) * 1999-03-30 2011-04-20 ノバルティス アーゲー 炎症性疾患治療用フタラジン誘導体

Also Published As

Publication number Publication date
CN1378543A (zh) 2002-11-06
ATE265448T1 (de) 2004-05-15
AU6895400A (en) 2001-03-05
JP2003506447A (ja) 2003-02-18
DE60010280D1 (de) 2004-06-03
DE60010280T2 (de) 2009-10-15
AR025068A1 (es) 2002-11-06
WO2001010859A1 (en) 2001-02-15
EP1208096B1 (en) 2004-04-28
EP1208096A1 (en) 2002-05-29
NO20020569L (no) 2002-04-10
ZA200200691B (en) 2003-10-29
ES2219382T3 (es) 2004-12-01
CA2381621A1 (en) 2001-02-15
NZ517087A (en) 2004-05-28
CO5180637A1 (es) 2002-07-30
BR0013113A (pt) 2002-04-30
MXPA02001324A (es) 2002-07-22
AU775237B2 (en) 2004-07-22
IL147885A0 (en) 2002-08-14
NO20020569D0 (no) 2002-02-05
KR20020019969A (ko) 2002-03-13

Similar Documents

Publication Publication Date Title
PE20010494A1 (es) Piridazinas sustituidas y piridazinas fusionadas con actividad inhibidora de la angiogenesis
ATE123771T1 (de) Stickstoff enthaltende heterozyklische verbindungen, ihre herstellung und verwendung.
ATE139233T1 (de) Annelierte thiophen-derivate, ihre herstellung und verwendung
PE52499A1 (es) Ftalazinas
DE3781080D1 (de) 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
NO178067C (no) Analogifremgangsmåte til fremstilling av terapautisk aktive heterocykliske forbindelser
AR021297A1 (es) 2-fenilbenzimidazoles y 2-fenilindoles, su preparacion y aplicacion
PE20010607A1 (es) Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
DE69105659D1 (de) 3-Arylindol- und 3-Arylindazolderivate.
KR880002829A (ko) 디하이드로피리딘 항알러지제 및 소염제
KR880013920A (ko) 디하이드로피리딘 화합물 및 이의 제조방법
DE3776044D1 (de) Pyridazinon-derivate.
EP0598123A4 (en) PIPERAZINE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING THEM.
KR910000755A (ko) 세로토닌 2-수용체 길항활성을 갖는 헤테로사이클릭 화합물
DE68926810D1 (de) Benzoxazepinon-Verfahren
ATE137747T1 (de) Aminobenzolverbindungen, herstellung und verwendung
AR027035A1 (es) Pirroles sustituidos
ES2112470T3 (es) Derivados de piridazinona, procedimientos de produccion y utilizacion.
EG19396A (en) Pesticidal heterocyclic compounds
KR890000478A (ko) 에르골린 유도체
KR940007008A (ko) 1, 3, 4-벤조트리아제핀-5(4h)-온 유도체 및 이것의 제조 방법
GEP19970838B (en) Process for obtaining 3-(methyltio, methylsulphinyl or methylsulphonyl)-4-quinolone
KR880010771A (ko) 이미다졸-2-티온 화합물로 제관류 손상을 경감시키는 방법

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FC Refusal